Most certainly TB. We will get the LAVENDER results after the last of the 180 patients has finished the 12 weeks of treatment and the data has been unblinded and analysed. Point about your comment is that it certainly won't be this year. ACADIA has already announced that the anticipated date for that is late 2021. All we might hear trial wise is progressive enrollment figures and (hopefully) no toxicity related problems as the trial progresses.So over the next 20 or more months all will be pretty quiet on the LAVENDER front, especially with regard to soul stirring news.
NEU Price at posting:
$2.65 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)